Evidence map›Paper›PMID 35690868›Full record

ArticleMolecular neurodegeneration2022

Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia.

Dan Xia, Steve Lianoglou, Thomas Sandmann, Meredith Calvert, Jung H Suh, Elliot Thomsen, Jason Dugas, Michelle E Pizzo, Sarah L DeVos, Timothy K Earr and 38 more

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Increased Amyloidogenic Neuronal Injury in HIV-1-infected APP-KI Alzheimer's disease mice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Assessment of early-phase [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 8 institutions in 2 countries.

Dan Xia *Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Steve Lianoglou *Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Thomas SandmannDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Meredith CalvertDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Jung H SuhDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Elliot ThomsenDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Jason DugasDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Michelle E PizzoDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Sarah L DeVosDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Timothy K EarrDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Chia-Ching LinDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Sonnet DavisDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Connie HaDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Amy Wing-Sze LeungDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Hoang NguyenDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Roni ChauDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Ernie YulyaningsihDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Isabel LopezDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Hilda SolanoyDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Shababa T MasoudDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Chun-Chi LiangDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Karin LinDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Giuseppe AstaritaDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Nathalie KhouryDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Joy Yu ZucheroDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Robert G ThorneDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Kevin ShenGladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.
Stephanie MillerGladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.
Jorge J PalopGladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.
Dylan GarceauThe Jackson Lab, Bar Harbor, Maine, USA.
Michael SasnerThe Jackson Lab, Bar Harbor, Maine, USA.
Jennifer D WhitesellAllen Institute for Brain Science, Seattle, Washington, USA.
Julie A HarrisAllen Institute for Brain Science, Seattle, Washington, USA.
Selina HummelGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.
Johannes GnörichGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.
Karin WindGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.
Lea KunzeGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.
Artem ZatcepinGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.
Matthias BrendelGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.
Michael WillemDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Christian HaassGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.
Daniel BarnettAppel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.
Till S ZimmerAppel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.
Anna G OrrAppel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.
Kimberly Scearce-LevieDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Joseph W LewcockDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Gilbert Di PaoloDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.
Pascal E SanchezDenali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA. sanchez@dnli.com.ORCID 0000-0002-2620-5165
Denali Therapeutics (United States) · USGerman Center for Neurodegenerative Diseases · DECornell University · USGladstone Institutes · USAllen Institute for Brain Science · USJackson Laboratory · USLMU Klinikum · DEUniversity of Minnesota · US

Funding

Project 4: Cross-species Dissection of Cellular Response to APOE Genotype and AD Pathology Using Single-cell Multi-omicsP01AG073082 · NIA · J. DAVID GLADSTONE INSTITUTES · PI HUANG, YADONG, MUCKE, LENNART · 2021 to 2025
$23.4M
Optogenetic dissection of cellular and circuit mechanisms of network dysfunction and amyloid deposition in mouse models of Alzheimer's disease in vivoRF1AG062234 · NIA · J. DAVID GLADSTONE INSTITUTES · PI PALOP, JORGE J · 2018 to 2021
$3.8M
Deciphering molecular pathways of inhibitory interneuron dysfunction in Alzheimer's diseaseR01AG062629 · NIA · J. DAVID GLADSTONE INSTITUTES · PI PALOP, JORGE J · 2019 to 2023
$3.6M
Mouse Cell Type-Specific Brain Mapping in Health and DiseaseR01AG047589 · NIA · ALLEN INSTITUTE · PI HARRIS, JULIE · 2014 to 2018
$3.4M
Mitochondrial Complex III Free Radicals in Dementia-Related Proteinopathy and NeuroinflammationR01AG068091 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ORR, ANNA GOLDSHMIDT · 2020 to 2024
$3.1M
Defining the Effects of Astrocytic TDP-43 Dysregulation on Hippocampal FunctionRF1NS118569 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI ORR, ANNA GOLDSHMIDT · 2020 to 2020
$2.2M
NIA NIH HHS P01 AG073082NIA NIH HHS R01 AG047589NIA NIH HHS R01 AG062629NIA NIH HHS R01 AG068091NIA NIH HHS RF1 AG062234NINDS NIH HHS RF1 NS118569
6 · The paper itself

Abstract

backgroundGenetic mutations underlying familial Alzheimer's disease (AD) were identified decades ago, but the field is still in search of transformative therapies for patients. While mouse models based on overexpression of mutated transgenes have yielded key insights in mechanisms of disease, those models are subject to artifacts, including random genetic integration of the transgene, ectopic expression and non-physiological protein levels. The genetic engineering of novel mouse models using knock-in approaches addresses some of those limitations. With mounting evidence of the role played by microglia in AD, high-dimensional approaches to phenotype microglia in those models are critical to refine our understanding of the immune response in the brain.

methodsWe engineered a novel App knock-in mouse model (App

resultsLeveraging multi-omics approaches, we discovered profound alteration of diverse lipids and metabolites as well as an exacerbated disease-associated transcriptomic response in microglia with high intracellular Aβ content. The App DISCUSSION: Our findings demonstrate that fibrillar Aβ in microglia is associated with lipid dyshomeostasis consistent with lysosomal dysfunction and foam cell phenotypes as well as profound immuno-metabolic perturbations, opening new avenues to further investigate metabolic pathways at play in microglia responding to AD-relevant pathogenesis. The in-depth characterization of pathological hallmarks of AD in this novel and open-access mouse model should serve as a resource for the scientific community to investigate disease-relevant biology.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAmyloid beta-PeptidesAmyloidosisAnimalsBrainDisease Models, AnimalMiceMice, TransgenicMicrogliaPlaque, AmyloidReceptors, GABAAmyloid beta-PeptidesAmyloid beta-Protein PrecursorReceptors, GABATSPO protein, humanAstrogliosisLipid dyshomeostasisNeuritic plaquesNeurodegenerationPhagocytic microgliaVascular amyloid

Identifiers

PMID35690868
PMCPMC9188195
OpenAlexW4282918923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.